Health resource utilization associated with skeletal-related events: results from a retrospective European study

被引:19
作者
Body, Jean-Jacques [1 ]
Pereira, Joao [2 ]
Sleeboom, Harm [3 ]
Maniadakis, Nikos [4 ]
Terpos, Evangelos [5 ]
Acklin, Yves Pascal [6 ]
Finek, Jindrich [7 ]
Gunther, Oliver [8 ]
Hechmati, Guy [9 ]
Mossman, Tony [10 ]
Costa, Luis [11 ]
Rogowski, Wojciech [12 ]
Nahi, Hareth [13 ]
von Moos, Roger [6 ]
机构
[1] Univ Libre Bruxelles, CHU Brugmann, Brussels, Belgium
[2] Univ Nova Lisboa, Natl Sch Publ Hlth, Lisbon, Portugal
[3] Haga Hosp, The Hague, Netherlands
[4] Natl Sch Publ Hlth, Dept Hlth Serv Management, Athens, Greece
[5] Univ Athens, Sch Med, Alexandra Univ Hosp, Athens, Greece
[6] Kantonsspital Graubunden, Chur, Switzerland
[7] Univ Hosp, Plzen, Czech Republic
[8] Amgen Ltd, Ctr Observat Res, Uxbridge, Middx, England
[9] Amgen Europe GmbH, Hlth Econ, Zug, Switzerland
[10] Amgen Ltd, Biostat, Cambridge, England
[11] Hosp Santa Maria, Inst Med Mol, Serv Oncol, Lisbon, Portugal
[12] ZOZ MSWiA Z Warminsko Mazurskim Ctr Onkol, Olszytn, Poland
[13] Karolinska Inst, Dept Med, Div Hematol, Stockholm, Sweden
关键词
Health resource utilization (HRU); Skeletalrelated event (SRE); Bone metastases; Breast cancer; Prostate cancer; Lung cancer; CLINICAL-PRACTICE GUIDELINES; RESISTANT PROSTATE-CANCER; METASTATIC BREAST-CANCER; PLACEBO-CONTROLLED TRIAL; BONE METASTASES; ZOLEDRONIC ACID; FOLLOW-UP; SOLID TUMORS; LUNG-CANCER; COST-EFFECTIVENESS;
D O I
10.1007/s10198-015-0716-7
中图分类号
F [经济];
学科分类号
020101 [政治经济学];
摘要
Background Bone complications, also known as skeletal-related events (SREs), are common in patients with bone metastases secondary to advanced cancers. Objective To provide a detailed estimate of the health resource utilization (HRU) burden associated with SREs across eight European countries. Methods Eligible patients from centers in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden, and Switzerland with bone metastases or lesions secondary to breast cancer, prostate, or lung cancer or multiple myeloma who had experienced at least one SRE (defined as radiation to bone, long-bone pathologic fracture, other bone pathologic fracture, surgery to bone or spinal cord compression) were entered into this study. HRU data were extracted retrospectively from the patients' charts from 3.5 months before the index SRE until 3 months after the index SRE (defined as an SRE preceded by an SRE-free period of at least 6.5 months). Results Overall, the mean number of inpatient stays per SRE increased from baseline by approximately 0.5-1.5 stays, with increases in the total duration of inpatient stays of approximately 6-37 days per event. All SREs were associated with substantial increases from baseline in the frequency of procedures and the number of outpatient and day-care visits. Conclusions SREs are associated with substantial HRU owing to considerable increases in the number and duration of inpatient stays, and in the number of procedures, outpatient visits, and day-care visits. These data collectively provide a valuable summary of the real-world SRE burden on European healthcare systems.
引用
收藏
页码:711 / 721
页数:11
相关论文
共 41 条
[1]
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial [J].
Barrett-Lee, Peter ;
Casbard, Angela ;
Abraham, Jacinta ;
Hood, Kerenza ;
Coleman, Robert ;
Simmonds, Peter ;
Timmins, Hayley ;
Wheatley, Duncan ;
Grieve, Robert ;
Griffithst, Gareth ;
Murray, Nick .
LANCET ONCOLOGY, 2014, 15 (01) :114-122
[2]
EANM procedure guideline for treatment of refractory metastatic bone pain [J].
Bodei, Lisa ;
Lam, Marnix ;
Chiesa, Carlo ;
Flux, Glenn ;
Brans, Boudewijn ;
Chiti, Arturo ;
Giammarile, Francesco .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (10) :1934-1940
[3]
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405
[4]
Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases [J].
Botteman, M. ;
Barghout, V. ;
Stephens, J. ;
Hay, J. ;
Brandman, J. ;
Aapro, M. .
ANNALS OF ONCOLOGY, 2006, 17 (07) :1072-1082
[5]
Review of patterns of practice and patients' preferences in the treatment of bone metastases with palliative radiotherapy [J].
Bradley, Nicole M. E. ;
Husted, Janice ;
Sey, Michael Sai Lai ;
Husain, Amna E. ;
Sinclair, Emily ;
Harris, Kristin ;
Chow, Edward .
SUPPORTIVE CARE IN CANCER, 2007, 15 (04) :373-385
[6]
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Cardoso, F. ;
Harbeck, N. ;
Fallowfield, L. ;
Kyriakides, S. ;
Senkus, E. .
ANNALS OF ONCOLOGY, 2012, 23 :11-19
[7]
Casas A, 2012, SUPPORT CARE CANCER, V20, pS88
[8]
Bone health in cancer patients: ESMO Clinical Practice Guidelines [J].
Coleman, R. ;
Body, J. J. ;
Aapro, M. ;
Hadji, P. ;
Herrstedt, J. .
ANNALS OF ONCOLOGY, 2014, 25 :124-137
[9]
Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO
[10]
2-G